Publications by authors named "Jerry Y Hsu"

Claim this Profile
F
FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).
Alexander Spira, Byoung Chul Cho, Enriqueta Felip, Edward B Garon, Koichi Goto, Jerry Y Hsu

Lung Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent -Sparing PI3K Inhibitor in Rats, Dogs, and Humans.
Shuguang Ma, Sungjoon Cho, Srikumar Sahasranaman, Weiping Zhao, Jodie Pang, Jerry Y Hsu

Drug Metab Dispos· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Cristina Saura, Dominik Hlauschek, Mafalda Oliveira, Dimitrios Zardavas, Anita Jallitsch-Halper, Jerry Y Hsu

Lancet Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
Maura N Dickler, Cristina Saura, Donald A Richards, Ian E Krop, Andrés Cervantes, Jerry Y Hsu

Clin Cancer Res· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Dejan Juric, Ian Krop, Ramesh K Ramanathan, Timothy R Wilson, Joseph A Ware, Jerry Y Hsu

Cancer Discov· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Jerry Y Hsu, Heather A Wakelee

BioDrugs· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pemetrexed disodium for the treatment of NSCLC: an update.
Jerry Y Hsu, Heather Wakelee

Drugs Today (Barc)· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncogenic regulators and substrates of the anaphase promoting complex/cyclosome are frequently overexpressed in malignant tumors.
Norman L Lehman, Rob Tibshirani, Jerry Y Hsu, Yasodha Natkunam, Brent T Harris

Am J Pathol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overexpression of the anaphase promoting complex/cyclosome inhibitor Emi1 leads to tetraploidy and genomic instability of p53-deficient cells.
Norman L Lehman, Emmy W Verschuren, Jerry Y Hsu, Athena M Cherry, Peter K Jackson

Cell Cycle· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophase destruction of Emi1 by the SCF(betaTrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase.
Florence Margottin-Goguet, Jerry Y Hsu, Alexander Loktev, Harn Mei Hsieh, Julie D R Reimann

Dev Cell· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Control of the centriole and centrosome cycles by ubiquitination enzymes.
David V Hansen, Jerry Y Hsu, Brett K Kaiser, Peter K Jackson, Adam G Eldridge

Oncogene· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1).
Jerry Y Hsu, Julie D R Reimann, Claus S Sørensen, Jiri Lukas, Peter K Jackson

Nat Cell Biol· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis